Mellman leaving gRED as part of oncology restructuring

Genentech Inc. confirmed the departure of VP Ira Mellman and the restructuring of Genentech Research and Early Development (gRED) to combine cancer immunology and molecular oncology. The company is also moving discovery functions within the Department of Human Pathobiology & OMNI Reverse Translation to the Departments of Immunology and Neuroscience in Research Biology. Genentech added that “a limited number of employees” will be affected.

Mellman joined Genentech in 2007 and led the cancer immunology group for 12 years, cutting the trail for the company’s entry into cell therapy and personalized cancer vaccines. He is also a professor at University of California San Francisco and is credited with discovering endosomes. ...